SLC5A2 and hydrops fetalis: Unlike with T2D, where we can use traditional HF therapy in combination with SGLT2-is, glucagon-like peptide 1 (GLP-1) agonists, and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists to improve CV prognosis, T1D therapy is still mainly based on insulin replacement.